Eble JN, Sauter G., Epstein JI, Sesterhenn IA - iarc

1486. Levin HS, Mostofi FK (1970).
Symptomatic plasmacytoma of the testis.
Cancer 25: 1193-1203.
1487. Levine RL (1980). Urethral cancer.
Cancer 45: 1965-1972.
1488. Li B, Kanamaru H, Noriki S,
Yamaguchi T, Fukuda M, Okada K (1998).
Reciprocal expression of bcl-2 and p53
oncoproteins in urothelial dysplasia and
carcinoma of the urinary bladder. Urol Res
26: 235-241.
1489. Li FP, Cassady JR, Jaffe N (1975). Risk
of second tumors in survivors of childhood
cancer. Cancer 35: 1230-1235.
1490. Li FP, Fraumeni JF (1972). Testicular
cancers in children: epidemiologic characteristics.
J Natl Cancer Inst 48: 1575-1581.
1491. Li J, Yen C, Liaw D, Podsypanina K,
Bose S, Wang SI, Puc J, Miliaresis C,
Rodgers L, McCombie R, Bigner SH,
Giovanella BC, Ittmann M, Tycko B,
Hibshoosh H, Wigler MH, Parsons R (1997).
PTEN, a putative protein tyrosine phosphatase
gene mutated in human brain,
breast, and prostate cancer. Science 275:
1943-1947.
1492. Li M, Cannizzaro LA (1999). Identical
clonal origin of synchronous and metachronous
low-grade, noninvasive papillary transitional
cell carcinomas of the urinary tract.
Hum Pathol 30: 1197-1200.
1493. Li M, Squire JA, Weksberg R (1998).
Molecular genetics of Wiedemann-
Beckwith syndrome. Am J Med Genet 79:
253-259.
1494. Lianes P, Charytonowicz E, Cordon-
Cardo C, Fradet Y, Grossman HB, Hemstreet
GP, Waldman FM, Chew K, Wheeless LL,
Faraggi D (1998). Biomarker study of primary
nonmetastatic versus metastatic
invasive bladder cancer. National Cancer
Institute Bladder Tumor Marker Network.
Clin Cancer Res 4: 1267-1271.
1495. Lianes P, Orlow I, Zhang ZF, Oliva MR,
Sarkis AS, Reuter VE, Cordon-Cardo C
(1994). Altered patterns of MDM2 and TP53
expression in human bladder cancer. J Natl
Cancer Inst 86: 1325-1330.
1496. Lichtenstein P, Holm NV, Verkasalo
PK, Iliadou A, Kaprio J, Koskenvuo M,
Pukkala E, Skytthe A, Hemminki K (2000).
Environmental and heritable factors in the
causation of cancer—analyses of cohorts
of twins from Sweden, Denmark, and
Finland. N Engl J Med 343: 78-85.
1497. Lieber MM, Tomera KM, Farrow GM
(1981). Renal oncocytoma. J Urol 125: 481-
485.
1498. Lilja H (1993). Significance of different
molecular forms of serum PSA. The free,
noncomplexed form of PSA versus that
complexed to alpha 1-antichymotrypsin.
Urol Clin North Am 20: 681-686.
1499. Lilja H, Christensson A, Dahlen U,
Matikainen MT, Nilsson O, Pettersson K,
Lovgren T (1991). Prostate-specific antigen
in serum occurs predominantly in complex
with alpha 1-antichymotrypsin. Clin Chem
37: 1618-1625.
1500. Lilleby W, Paus E, Skovlund E, Fossa
SD (2001). Prognostic value of neuroendocrine
serum markers and PSA in irradiated
patients with pN0 localized prostate
cancer. Prostate 46: 126-133.
1501. Lim DJ, Hayden RT, Murad T, Nemcek
AAJr, Dalton DP (1993). Multilocular prostatic
cystadenoma presenting as a large complex
pelvic cystic mass. J Urol 149: 856-859.
1502. Limmer S, Wagner T, Leipprand E,
Arnholdt H (2001). [Primary renal hemangiosarcoma.
Case report and review of the
literature]. Pathologe 22: 343-348.
1503. Lin DW, Thorning DR, Krieger JN
(1999). Primary penile lymphoma: diagnostic
difficulties and management options.
Urology 54: 366.
1504. Lin JI, Yong HS, Tseng CH, Marsidi PS,
Choy C, Pilloff B (1980). Diffuse cystitis glandularis.
Associated with adenocarcinomatous
change. Urology 15: 411-415.
1505. Lin X, Tascilar M, Lee WH, Vles WJ,
Lee BH, Veeraswamy R, Asgari K, Freije D,
van Rees B, Gage WR, Bova GS, Isaacs WB,
Brooks JD, de Weese TL, de Marzo AM,
Nelson WG (2001). GSTP1 CpG island hypermethylation
is responsible for the absence of
GSTP1 expression in human prostate cancer
cells. Am J Pathol 159: 1815-1826.
1506. Lindau A (1926). Studien uber
Kleinhirncysten. Bau, Pathogenese und
Beziehungen zur Angiomatosis Retinae.
Acta Pathol Microbiol Scand Suppl 1.
1507. Linnenbach AJ, Robbins SL, Seng BA,
Tomaszewski JE, Pressler LB, Malkowicz SB
(1994). Urothelial carcinogenesis. Nature
367: 419-420.
1508. Linnoila RI, Keiser HR, Steinberg SM,
Lack EE (1990). Histopathology of benign versus
malignant sympathoadrenal paragangliomas:
clinicopathologic study of 120
cases including unusual histologic features.
Hum Pathol 21: 1168-1180.
1509. Lipponen P (1993). Expression of c-
erbB-2 oncoprotein in transitional cell bladder
cancer. Eur J Cancer 29A: 749-753.
1510. Lipponen P, Eskelinen M (1994).
Expression of epidermal growth factor
receptor in bladder cancer as related to
established prognostic factors, oncoprotein
(c-erbB-2, p53) expression and long-term
prognosis. Br J Cancer 69: 1120-1125.
1511. Lipponen PK, Eskelinen MJ (1995).
Reduced expression of E-cadherin is related
to invasive disease and frequent recurrence
in bladder cancer. J Cancer Res Clin Oncol
121: 303-308.
1512. Lipponen PK, Nordling S, Eskelinen MJ,
Jauhiainen K, Terho R, Harju E (1993). Flow
cytometry in comparison with mitotic index
in predicting disease outcome in transitional-cell
bladder cancer. Int J Cancer 53: 42-47.
1513. Little NA, Wiener JS, Walther PJ,
Paulson DF, Anderson EE (1993). Squamous
cell carcinoma of the prostate: 2 cases of a
rare malignancy and review of the literature.
J Urol 149: 137-139.
1514. Litton M, Bergeron C (1987). [Primary
lymphoma of the penis]. J Urol (Paris) 93: 99-
101.
1515. Liu JB, Bagley DH, Conlin MJ, Merton
DA, Alexander AA, Goldberg BB (1997).
Endoluminal sonographic evaluation of
ureteral and renal pelvic neoplasms. J
Ultrasound Med 16: 515-521.
1516. Liu Q, Schwaller J, Kutok J, Cain D,
Aster JC, Williams IR, Gilliland DG (2000).
Signal transduction and transforming properties
of the TEL-TRKC fusions associated
with t(12;15)(p13;q25) in congenital fibrosarcoma
and acute myelogenous leukemia.
EMBO J 19: 1827-1838.
1517. Liukkonen T, Lipponen P, Raitanen M,
Kaasinen E, Ala-Opas M, Rajala P, Kosma
VM (2000). Evaluation of p21WAF1/CIP1 and
cyclin D1 expression in the progression of
superficial bladder cancer. Finbladder
Group. Urol Res 28: 285-292.
1518. Liukkonen T, Rajala P, Raitanen M,
Rintala E, Kaasinen E, Lipponen P (1999).
Prognostic value of MIB-1 score, p53, EGFr,
mitotic index and papillary status in primary
superficial (Stage pTa/T1) bladder cancer: a
prospective comparative study. The
Finnbladder Group. Eur Urol 36: 393-400.
1519. Lloyd DA, Rintala RJ (1998). Inguinal
hernia and hydrocele. In: Pediatric
Surgery, JA O’Neill, MI Rowe, JL Grosfeld,
EW Fonkalsrud, AG Coran, eds. 5 th Edition.
Mosby: St Louis, p. 1071.
1520. Lloyd RV, Erickson LA, Jin L, Kulig E,
Qian X, Cheville JC, Scheithauer BW
(1999). p27kip1: a multifunctional cyclindependent
kinase inhibitor with prognostic
significance in human cancers. Am J
Pathol 154: 313-323.
1521. Lloyd SN, Collins GN, McKelvie GB,
Hehir M, Rogers AC (1994). Predicted and
actual change in serum PSA following
prostatectomy for BPH. Urology 43: 472-
479.
1522. Lobe TE, Wiener E, Andrassy RJ,
Bagwell CE, Hays D, Crist WM, Webber B,
Breneman JC, Reed MM, Tefft MC, Heyn R
(1996). The argument for conservative,
delayed surgery in the management of prostatic
rhabdomyosarcoma. J Pediatr Surg
31: 1084-1087.
1523. Lodato RF, Zentner GJ, Gomez CA,
Nochomovitz LE (1991). Scrotal carcinoid.
Presenting manifestation of multiple
lesions in the small intestine. Am J Clin
Pathol 96: 664-668.
1524. Loeb LA (2001). A mutator phenotype
in cancer. Cancer Res 61: 3230-3239.
1525. Loehrer PJSr, Hui S, Clark S, Seal M,
Einhorn LH, Williams SD, Ulbright T,
Mandelbaum I, Rowland R, Donohue JP
(1986). Teratoma following cisplatin-based
combination chemotherapy for nonseminomatous
germ cell tumors: a clinicopathological
correlation. J Urol 135: 1183-
1189.
1526. Loening SA, Jacobo E, Hawtrey CE,
Culp DA (1978). Adenocarcinoma of the
urachus. J Urol 119: 68-71.
1527. Lofts FJ, Gullick WJ (1992). c-erbB2
amplification and overexpression in human
tumors. Cancer Treat Res 61: 161-179.
1528. Logothetis CJ, Dexeus FH, Chong C,
Sella A, Ayala AG, Ro JY, Pilat S (1989).
Cisplatin, cyclophosphamide and doxorubicin
chemotherapy for unresectable
urothelial tumors: the M.D. Anderson
experience. J Urol 141: 33-37.
1529. Logothetis CJ, Samuels ML, Selig DE,
Ogden S, Dexeus F, Swanson D, Johnson
D, von Eschenbach A (1986). Cyclic
chemotherapy with cyclophosphamide,
doxorubicin, and cisplatin plus vinblastine
and bleomycin in advanced germinal
tumors. Results with 100 patients. Am J
Med 81: 219-228.
1530. Logothetis CJ, Xu HJ, Ro JY, Hu SX,
Sahin A, Ordonez N, Benedict WF (1992).
Altered expression of retinoblastoma protein
and known prognostic variables in
locally advanced bladder cancer. J Natl
Cancer Inst 84: 1256-1261.
1531. Lohrisch C, Murray N, Pickles T,
Sullivan L (1999). Small cell carcinoma of
the bladder: long term outcome with integrated
chemoradiation. Cancer 86: 2346-
2352.
1532. Lohse CM, Blute ML, Zincke H,
Weaver AL, Cheville JC (2002). Comparison
of standardized and nonstandardized
nuclear grade of renal cell carcinoma to
predict outcome among 2,042 patients. Am
J Clin Pathol 118: 877-886.
1533. Lonergan KM, Iliopoulos O, Ohh M,
Kamura T, Conaway RC, Conaway JW,
Kaelin WGJr (1998). Regulation of hypoxiainducible
mRNAs by the von Hippel-Lindau
tumor suppressor protein requires binding
to complexes containing elongins B/C and
Cul2. Mol Cell Biol 18: 732-741.
1534. Lonn U, Lonn S, Friberg S, Nilsson B,
Silfversward C, Stenkvist B (1995).
Prognostic value of amplification of c-erb-
B2 in bladder carcinoma. Clin Cancer Res
1: 1189-1194.
1535. Lont AP, Besnard APE, Gallee MP,
van Tinteren H, Horenblas S (2003). A comparison
of physical examination and imaging
in determining the extent of primary
penile carcinoma. BJU Int 91: 493-495.
1536. Looijenga LH, Abraham M, Gillis AJ,
Saunders GF, Oosterhuis JW (1994).
Testicular germ cell tumors of adults show
deletions of chromosomal bands 11p13 and
11p15.5, but no abnormalities within the
zinc-finger regions and exons 2 and 6 of the
Wilms’ tumor 1 gene. Genes Chromosomes
Cancer 9: 153-160.
1537. Looijenga LH, de Munnik H,
Oosterhuis JW (1999). A molecular model
for the development of germ cell cancer.
Int J Cancer 83: 809-814.
1538. Looijenga LH, Gillis AJ, van Gurp RJ,
Verkerk AJ, Oosterhuis JW (1997). X inactivation
in human testicular tumors. XIST
expression and androgen receptor methylation
status. Am J Pathol 151: 581-590.
1539. Looijenga LH, Olie RA, van der Gaag I,
van Sluijs FJ, Matoska J, Ploem-Zaaijer J,
Knepfle C, Oosterhuis JW (1994).
Seminomas of the canine testis. Counterpart
of spermatocytic seminoma of men?
Lab Invest 71: 490-496.
1540. Looijenga LH, Oosterhuis JW (1999).
Pathogenesis of testicular germ cell
tumours. Rev Reprod 4: 90-100.
1541. Looijenga LH, Oosterhuis JW (2002).
Pathobiology of testicular germ cell
tumors: views and news. Anal Quant Cytol
Histol 24: 263-279.
1542. Looijenga LH, Oosterhuis JW,
Ramaekers FC, de Jong B, Dam A, Beck JL,
Sleijfer DT, Schraffordt Koops H (1991).
Dual parameter flow cytometry for deoxyribonucleic
acid and intermediate filament
proteins of residual mature teratoma. All
tumor cells are aneuploid. Lab Invest 64:
113-117.
1543. Looijenga LH, Rosenberg C, van Gurp
RJ, Geelen E, Echten-Arends J, de Jong B,
Mostert M, Oosterhuis WJ (2000).
Comparative genomic hybridization of
microdissected samples from different
stages in the development of a seminoma
and a non-seminoma. J Pathol 191: 187-192.
1544. Looijenga LH, Verkerk AJ, de Groot N,
Hochberg AA, Oosterhuis JW (1997). H19 in
normal development and neoplasia. Mol
Reprod Dev 46: 419-439.
1545. Looijenga LH, Zafarana G,
Grygalewitcz B, Summersgill B, Debiec-
Rychter M, Veltman J, Shoenmakers
EFPM, Rodriguez S, Jafer O, Clark J, Geurts
van Kessel A, Shipley J, van Gurp RJ, Gillis
AJM, Oosterhuis JW (2003). Role of gain of
12p in germ cell tumour development.
APMIS 111: 161-171.
1546. Lopes A, Bezerra AL, Pinto CA,
Serrano SV, de Mello CA, Villa LL (2002).
p53 as a new prognostic factor for lymph
node metastasis in penile carcinoma:
analysis of 82 patients treated with amputation
and bilateral lymphadenectomy. J
Urol 168: 81-86.
1547. Lopez-Beltran A, Cheng L, Andersson
L, Brausi M, de Matteis A, Montironi R,
Sesterhenn I, van der Kwast T, Mazerolles
C (2002). Preneoplastic non-papillary
lesions and conditions of the urinary bladder:
an update based on the Ancona
International Consultation. Virchows Arch
440: 3-11.
References 329